WRPWM
RXRX icon

Werba Rubin Papier Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Werba Rubin Papier Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Hold
37,155
– – 0.02% 305
2026
Q1 		$114K Sell
37,155
-839
-2% -$3.24K 0.02% 276
2025
Q4 		$155K Buy
+37,994
New +$188K 0.04% 229

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Werba Rubin Papier Wealth Management's RXRX Position: Q2 2026 in Review

Werba Rubin Papier Wealth Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 37,155 shares worth $136K. The position accounts for 0.02% of the portfolio, ranked #305.

Werba Rubin Papier Wealth Management first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $155K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Werba Rubin Papier Wealth Management held 37,155 shares of Recursion Pharmaceuticals worth $136K as of Q2 2026.
  • Werba Rubin Papier Wealth Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up 0.02% of Werba Rubin Papier Wealth Management's portfolio in Q2 2026, its #305 holding.
  • Werba Rubin Papier Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Werba Rubin Papier Wealth Management's Recursion Pharmaceuticals position peaked at $155K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Werba Rubin Papier Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.